Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Organogenesis (ORGO) had Cost of Goods Sold of $49.92M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$225.61M |
|
$39.29M |
|
|
Cost of Goods Sold |
$49.92M |
$175.69M |
|
$162.32M |
|
$63.29M |
|
$0.14M |
|
$63.43M |
|
$63.43M |
|
$43.70M |
|
$43.70M |
|
$43.70M |
|
$43.70M |
|
$63.29M |
|
$70.30M |
|
126.74M |
|
130.25M |
|
$0.32 |
|
$0.31 |
|
| Balance Sheet Financials | |
$362.19M |
|
$103.71M |
|
$236.54M |
|
$598.73M |
|
$100.12M |
|
$12.79M |
|
$198.48M |
|
$298.60M |
|
$300.13M |
|
$262.21M |
|
$300.13M |
|
126.95M |
|
| Cash Flow Statement Financials | |
$-10.31M |
|
$-14.15M |
|
$-17.36M |
|
$136.15M |
|
$94.33M |
|
$-41.82M |
|
$13.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.62 |
|
-- |
|
-- |
|
0.04 |
|
0.07 |
|
77.87% |
|
28.05% |
|
28.05% |
|
-- |
|
28.11% |
|
17.42% |
|
$-24.46M |
|
-- |
|
-- |
|
-- |
|
0.38 |
|
1.68 |
|
1.04 |
|
86.75 |
|
14.56% |
|
16.67% |
|
7.30% |
|
13.97% |
|
$2.36 |
|
$-0.19 |
|
$-0.08 |
|